{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Levin MJ"],"funding":["U.S. Department of Health and Human Services","U.S. Department of Defense","AstraZeneca"],"pagination":["2188-2200"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9069994"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["386(23)"],"pubmed_abstract":["<h4>Background</h4>The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.<h4>Methods</h4>In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one contai"],"journal":["The New England journal of medicine"],"pubmed_title":["Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19."],"pmcid":["PMC9069994"],"funding_grant_id":["W911QY-21-9-0001"],"pubmed_authors":["Pham D","Psachoulia K","Laurichesse H","Wright N","Connaire J","Alappan R","Levinson DJ","Moka C","Rampling T","Bahrami G","Arends RH","Bertholon F","Martinot JB","De Wit S","Vila M","Ignacio Garcia JM","Ricamara M","Aleman F","Patel N","Ramanath V","Martin E","Buntinx E","Essink BJ","Onder R","Guillier A","Wijewardane P","Vallejo C","Biles D","Yuan Y","McMillan C","Near KA","Newton L","DeWeese RJ","Montgomery RL","Menendez-Perez I","Beavon R","Naguib SG","Streicher K","Estrada Perez V","Ochoa Castillo MD","Rawlins T","Bello V","Quintanilla Y","Crihfield L","Cano BM","Migaud MC","Donlin N","PROVENT Study Group","Amin F","Parikh R","Padilla KW","DiMarco H","Owens M","Vercammen I","Thomas R","Chateloin L","Elrezzi E","Raissi S","Burgos J","Torres D","Haamid S","Alozie O","Santiago E","Houlihan C","Bardou M","Kelly EJ","Sardou-Rabia D","Hopper WF","Hamal S","Vera E","Zapata JF","Gray R","Cordero M","Hafeez H","Cano Zaldivar M","Adams K","Pangalos MN","Reilly S","Manjunathappa AG","Wilson D","Baker H","Yim YTN","Echave-Sustaeta JM","De Langhe J","Cruz Jentoft A","Luu M","Nunez M","Bhat J","Comeche Casanova L","Snoeck C","Guimard T","Jacob R","So N","Lynn R","Deplanque D","Hernandez G","Betts J","Yousef J","Howie E","Caille-Fenerol C","Allavena C","Ramjee M","Mendoza G","Barus R","Botelho-Nevers E","Levin MJ","Cano MV","Keast S","Barnes L","Uriel A","Ruch C","Falcone L","Ball D","Esser MT","Fernandes J","Tan E","Koh GCKW","Launay O","Vishnepolsky M","Arora S","Llerena S","Anagua Melendres J","Dunn L","Molina JM","Raffi F","Aldea M","Libri V","Lecompte AS","Seegobin S","Froget R","Lewis A","Ross DL","Devilliers H","Etcheverry F","Whittley S","Chaudhry A","Ustianowski A","Garbes P","de Maeyer M","Zeig S","Riggs S","Ellery A","Sharbaugh A","Ralph R","Sullivan G","Dey K","Alexander L","Ismail C","Nava J","Del Nozal JM","Lee YC","Somers S","Sathyan S","Akharia O","Templeton A","Avila M","Gonzalez Cediel P","Siu B","Alcaide F","Baron M","Smith D","Bolster E","Anderson A","Capiau L","Ndikum J","Kordsmeier J","Brickel H","Anagua O","Buntinx L","Bollen H","Casanova LT","Jimenez E","Smith T","Dao M","Ambery P","Marine M","Kumar J","Frome A","Longley N","Cano G","Meulemeester M"],"additional_accession":[]},"is_claimable":false,"name":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.","description":"<h4>Background</h4>The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.<h4>Methods</h4>In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one contai","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2026-05-31T12:59:15.733Z","creation":"2025-04-06T21:50:09.871Z"},"accession":"S-EPMC9069994","cross_references":{"pubmed":["35443106"],"doi":["10.1056/NEJMoa2116620"]}}